TrialCancer immunology, immunotherapy : CII2019

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.

Inge M Werter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.